Han-Joo Kim
Company: Imnewrun Biosciences Inc.
Job title: Chief Executive Officer
Seminars:
TRANSMAB:PD-L1 – a Novel Therapeutic Strategy Targeting Reactive Astrocytes & Glial Checkpoint in Alzheimer’s Disease 1:45 pm
• Outlining the role of GFAP+ astrocytes in the neuroinflammatory cascade in neurodegeneration • Exploring PD-L1+ GFAP+ astrocyte and PD-1+ microglia as a glial checkpoint and a potential novel therapeutic target against Alzheimer’s Disease • Showcasing TRANSMAB:PD-L1 antibody ability to cross the BBB, reduce GFAP, and improve pathological outcome in preclinical AD modelsRead more
day: Day Two